Last reviewed · How we verify
NCT04779814: DANTE
Non-interventional Study Describing Healthcare Resource Utilisation and Clinical Outcomes Associated With VNS Therapy in UK.
trial in Epilepsy in 97 participants. Terminated before completion.
19 August 2025
Quick facts
| Lead sponsor | LivaNova |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 97 |
| Start date | 11 May 2021 |
| Primary completion | 19 August 2025 |
| Estimated completion | 19 August 2025 |
| Sites | 5 locations across United Kingdom |
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
LivaNova — full company profile →
Who can join
1 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a UK, multi-center, non-interventional study based on the use of health service administrative and medical records (paper-based and/or electronic, as applicable) along with the use of prospectively collected subject-reported outcomes on experience with use of VNS therapy using validated and bespoke self-completion questionnaires. Data for hospital resource utilisation will be extracted from the Hospital Episode Statistics (HES) database.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04779814
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other LivaNova trials
Trials by the same sponsor.
- NCT05975931 — IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes. · terminated
- NCT04950894 — Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation · NA · active not recruiting
- NCT04753385 — The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment mea · terminated
- NCT04282681 — XLTCS - Accelerometer Data Collection in an Epilepsy Monitoring Unit (EMU) · withdrawn
- NCT03887715 — A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04779814 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LivaNova
- Last refreshed: 25 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04779814.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing